The West Africa generic drug market is currently witnessing moderate growth. Generic drugs are bioequivalent of branded drugs in terms of their strength, dosage, safety, quality, performance and efficiency. These drugs are more affordable than their counterparts as the manufacturers do not need to invest in marketing or testing the efficiency and strength of these medicines. Since they are proven to be safe and effective as branded drugs, the demand for generic drugs is escalating in the West African region.
The increasing prevalence of infectious diseases, such as malaria, tuberculosis (TB), and acquired immune deficiency syndrome (AIDS), along with the outbreak of meningitis, polio, pandemic influenza, cholera, measles, hepatitis, tetanus and yellow fever, are positively influencing the demand for generic drugs in the West African region. Moreover, governing authorities of various countries are focusing on investing in the healthcare sectors to reduce the number of deaths caused by the lack of essential drugs. This, in turn, is driving the market of generic drugs in the region. However, the sudden outbreak of the coronavirus disease (COVID-19) and the implementation of lockdown restrictions have hampered the production of generic drugs in the region. The market will experience growth once lockdown restrictions are reduced. Looking forward, the market is expected to continue its moderate during the forecast period (2021-2026).
IMARC Group provides an analysis of the key trends in each sub-segment of the West Africa generic drug market report, along with forecasts for growth at the region level from 2021-2026. Our report has categorized the market based on region, segment, therapy area, drug delivery and distribution channel.
Breakup by Segment:
Breakup by Therapy Area:
Breakup by Drug Delivery:
Breakup by Distribution Channel:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at